Francesca Compagno

Scopus Publications

Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
Marie von Lilienfeld-Toal, Fareed Khawaja, Francesca Compagno, Christine Robin, José-Luis Piñana, Simone Cesaro, Hermann Einsele, Per Ljungman, David Navarro, Michael Boeckh, Roy F Chemaly, Hans H Hirsch
Lancet Infectious Diseases, 2026
To update recommendations of the 4th European Conference on Infections in Leukaemia (ECIL-4) on community-acquired respiratory virus (CARV) infections published in 2013, we reviewed publications from between Jan 1, 2014, and June 30, 2024 on adenovirus, bocavirus, coronavirus, influenzavirus, metapneumovirus, parainfluenzavirus, respiratory syncytial virus (RSV), and rhinovirus in patients with haematological malignancies or undergoing haematopoietic cell transplantation (HCT), or both. In the current ECIL recommendations (ECIL-10), we outline a common approach to infection control, laboratory testing, and diagnosis for all CARVs (including SARS-CoV-2) and specific management and deferral strategies for CARVs other than SARS-CoV-2. For influenzavirus, seasonal inactivated-vaccines and early antivirals are recommended, whereas routine antiviral prophylaxis is discouraged for immunocompromised patients. For RSV, licensed vaccines can be considered according to local approval, despite scarce evidence for patients with haematological malignancies and those undergoing HCT. Passive immunisation with palivizumab or nirsevimab is recommended for children younger than 2 years, but data are insufficient for pre-exposure or post-exposure prophylaxis, or treatment of older children and adults. Oral ribavirin or intravenous immunoglobulins, or a combination of the two, are recommended for patients undergoing HCT with severe immunodeficiency scores. For other CARVs, recommendations include only supportive care, improving immune functions, correcting hypogammaglobulinaemia, and judicious lowering of corticosteroids. We highlight unmet needs in immunisation and antivirals for reducing CARV-associated morbidity and mortality in patients with haematological malignancies and those undergoing HCT.
Universal Hip Ultrasound Screening in Newborns: A 21-Month Prospective Observational Study in a Spoke Center
Neftj Ragusa, Nefer Roberta Gianotto, Virginia Deut, Chiara Mattivi, Francesca Compagno, Marta Cherubini Scarafoni, Silvia Dominici, Massimo Berger
Medical Sciences, 2025
Background: Developmental dysplasia of the hip (DDH) encompasses a spectrum of neonatal hip abnormalities that, if not detected and treated early, may lead to long-term orthopedic sequelae. Universal ultrasound screening using Graf’s method has been proposed to improve early diagnosis, though its implementation remains heterogeneous in Italy. Objectives: This study aimed to describe the outcomes of a universal ultrasound screening program for DDH conducted in a first-level birth center in northern Italy, evaluating DDH incidence, risk factors, management outcomes, and program feasibility. Methods: A prospective observational study was conducted from February 2024 to October 2025 at the Ivrea birth center (Piedmont region, Italy). All consecutive live-born infants (n = 904) underwent hip ultrasound according to Graf’s method, between 0 and 11 weeks of age. Hips were classified as type I (normal), type IIa (physiologically immature), or type IIb–IV (pathological). Infants with type IIa hips were re-evaluated after 2–4 weeks; those with type IIb or worse were referred to pediatric orthopedics. Results: Of 1808 hips examined, 92% were Graf type I and 8% type IIa. After follow-up, 93% of type IIa hips matured spontaneously. Pathological DDH (Graf IIb or worse) was diagnosed in 8 infants (0.88%), of whom 75% were female; 50% had no identifiable risk factors. All affected infants were treated with harness before 12 weeks of age, with complete recovery and no late diagnoses. No infant required surgical treatment. Conclusions: Universal ultrasound screening for DDH was feasible and effective in a first-level birth center, ensuring early diagnosis and absence of late-presenting cases. These findings support universal screening as a safe and equitable approach to reduce DDH-related morbidity and align with national recommendations for standardized early detection programs.
Real-Life Use of Posaconazole in Clinical Practice for Onco-Hematological Children: A National Survey by AIEOP Infectious Diseases Working Group
Lorenzo Chiusaroli, Manuela Spadea, Cecilia Liberati, Maria Grazia Petris, Antonio Grasso, Francesco Baccelli, Maria Vittoria Micheletti, Pietro Gasperini, Maria Rosaria D’Amico, Katia Perruccio, Angelica Barone, Daniela Onofrillo, Paola Muggeo, Maura Faraci, Simona Rinieri, Ilaria Liguoro, Antonella Colombini, Francesca Trevisan, Nagua Giurici, Gianluca Boscarol, Letizia Pomponia Brescia, Alessia Pancaldi, Francesca Compagno, Alessandra Biffi, Daniele Donà, Simone Cesaro
Journal of Fungi, 2025
Background: Posaconazole is an antifungal medication used to treat invasive fungal infections (IFI) in pediatric onco-hematological patients. Its approval for pediatric use was recent, and limitations still apply. Despite limited data, the safety and efficacy profile appear generally favorable in children. This study describes how posaconazole is used across centers affiliated with the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP). Methods: A national survey was conducted among physicians within the AIEOP network to evaluate current use of posaconazole in pediatric cancer patients, including those undergoing hematopoietic stem cell transplantation (HSCT). A 25-item web questionnaire was developed and distributed in June 2024. Data analysis involved descriptive statistics. Results: Twenty-one of thirty-one centers (68%) responded, reporting availability of various posaconazole formulations: oral suspension (76%), delayed-release tablets (95%), and intravenous solution (14%). Posaconazole was primarily used for prophylaxis in patients with acute lymphoblastic leukemia (ALL, 38%), acute myeloid leukemia (AML, 38%), and aplastic anemia (19%). It was also used as secondary prophylaxis against previous possible or probable IFI or as salvage therapy for probable or confirmed aspergillosis or mucormycosis, often combined with other treatments. Drug plasma level monitoring was common but varied in scheduling across centers. Most centers (74%) discontinued posaconazole if adverse events suspected drug–drug interactions, such as with vincristine. Conclusions: Posaconazole is widely used in AIEOP centers, though application varies significantly. This variability emphasizes the need for prospective studies to better define indications, dosing, and monitoring protocols for pediatric use of this antifungal.
Food Safety Practices and Foodborne Illness in Italian Pediatric Oncology and Hematology Centers: A Survey on Behalf of the Infectious Disease Working Group of AIEOP
Davide Leardini, Gianluca Bossù, Francesco Venturelli, Francesco Baccelli, Edoardo Muratore, Antonio Grasso, Pietro Gasperini, Chiara Pilotto, Letizia Pomponia Brescia, Nagua Giurici, Angelica Barone, Mariacristina Menconi, Elena Soncini, Daniela Onofrillo, Manuela Spadea, Francesco Fabozzi, Pietro Casartelli, Simona Rinieri, Maria Grazia Petris, Valeria Petroni, Paola Muggeo, Katia Perruccio, Cristina Meazza, Francesca Compagno, Francesco Paolo Tambaro, Maura Faraci, Angela Mastronuzzi, Riccardo Masetti, Simone Cesaro
Pediatric Blood and Cancer, 2025
BackgroundFood safety practices are widely recommended for pediatric patients with cancer or undergoing hematopoietic stem cell transplantation (HCT) to mitigate foodborne infectious risks. However, specific measures, such as the neutropenic diet (ND) or low‐microbial diet, lack robust evidence and are inconsistently implemented across pediatric hematology‐oncology centers. Additionally, data on foodborne illnesses (FBI) in this population remain scarce.ProcedureWe conducted an online survey and a retrospective review of FBI cases across 22 centers within the Italian Association of Pediatric Hematology and Oncology (AIEOP) network, 13/22 performing allogeneic HCT.ResultsAll centers provide dietary recommendations to the patients. Restrictive diets are recommended in 72% of centers during hospitalization and in 77% after discharge. Universally avoided foods include unpasteurized milk, fresh fruit without skin, moldy cheeses, bakery and ice cream products, raw eggs and derivatives, raw meat, raw or smoked fish, cured meats, shellfish, and cooked food leftovers. Fresh fruits and vegetables are commonly restricted only to patients undergoing allogeneic HCT. Ninety‐five percent of centers provide patients and their families with guidelines on cleaning food at home, including thorough cleaning of fruits and vegetables with a food disinfectant. Seven centers reported FBI cases, with eight documented cases, including two fatalities caused by meningoencephalitis related to infections from Listeria monocytogenes and Bacillus cereus, respectively.ConclusionsThis study highlights the need for standardized, evidence‐based food safety guidelines and FBI management to enhance care for pediatric patients receiving chemotherapy or HCT.
The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP)
Francesco Baccelli, Francesca Compagno, Gloria Tridello, Francesco Delle Cave, Daniele Zama, Riccardo Masetti, Maria Grazia Petris, Lorenzo Chiusaroli, Manuela Spadea, Francesca Trevisan, Antonella Colombini, Samantha Conci, Cristina Meazza, Paola Muggeo, Maria Vittoria Micheletti, Alessia Pancaldi, Rosamaria Mura, Daniela Onofrillo, Raffaella De Santis, Milena La Spina, Elio Castagnola, Katia Perruccio, Angelica Barone, Nagua Giurici, Angelamaria Petrone, Federico Mercolini, Simona Rinieri, Simone Cesaro
British Journal of Haematology, 2025
SummaryUnderstanding bloodstream infection (BSI) epidemiology is crucial for optimizing antibiotic therapy in paediatric haematology–oncology patients undergoing chemotherapy or haematopoietic cell transplantation (HCT). However, updated paediatric data remain scarce. This multicentre retrospective study analysed BSI epidemiology across 22 Italian centres (2018–2019), assessing pathogens, resistance profiles, empirical antibiotic therapy (EAT) and clinical course with outcomes. Mortality risk factors were evaluated using a Cox regression model. A total of 510 BSI episodes occurred in 396 patients (median age 6.4 years), with an incidence of 2.9 and 5.1 per 1000 inpatient days for chemotherapy and HCT respectively. Multidrug‐resistant (MDR), third to fourth generation cephalosporin‐ and carbapenem‐resistant, account for 18.3%, 29.3% and 8.2% of Gram‐negative infections respectively. 42.2% of Klebsiella pneumoniae isolates were MDR. Combination EAT was used in 269/510 episodes, with piperacillin–tazobactam+amikacin being most common. Microbiological appropriateness was 82%. Infection‐related and 30‐day mortality rates were 4.1% and 5.29%, respectively, with appropriate EAT significantly reducing mortality. Our findings highlight the burden of resistant pathogens in paediatric BSIs and emphasize the importance of appropriate EAT in improving outcomes, underscoring the need for treatment strategies tailored to local resistance patterns.
Early HHV-6 reactivation increases the risk of graft rejection after haploidentical hematopoietic cell transplantation
Francesca Compagno, Stella Boghen, Tommaso Mina, Arianna Panigari, Annalisa Agostini, Marika De Cicco, Stella Muscianisi, Jennifer Zumelli, Claudia Del Fante, Cesare Perotti, Giovanna Giorgiani, Fausto Baldanti, Stefania Paolucci, Patrizia Comoli, Marco Zecca
Bone Marrow Transplantation, 2025
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)
Livio Pagano, Georg Maschmeyer, Frederic Lamoth, Ola Blennow, Alienor Xhaard, Manuela Spadea, Alessandro Busca, Catherine Cordonnier, Johan Maertens, , Manuela Aguilar Guisado, Murat Akova, Sophie Alain, Mahmoud Aljurf, Dina Averbuch, Francesco Baccelli, Nicole Blijlevens, Michael Boeckh, Thierry Calandra, Simone Cesaro, Roy Chemaly, Francesca Compagno, Rafael De La Camara, Thushan de Silva, Manuel Nuno Direito de Morais Guerreiro, Federica Galaverna, Carolina Garcia Vidal, Tobias Gedde-Dahl, Lidia Gil, Andreas Groll, Raoul Herbrecht, Hans Hirsch, Martin Hoenigl, Per Ljungman, Varun Mehra, Malgorzata Mikulska, Patricia Munoz, Anders Eivind Leren Myrhe, David Navarro, Dionysios Neofytos, Marcio Nucci, Chiara Oltolini, Agnieszka Piekarska, José Luis Pinana, Elena Reigadas Ramirez, Christine Robin, Alicja Sadowska-Klasa, Manuela Spadea, Ben Teh, Yuri Vanbiervliet, Lewis White
Leukemia, 2025
At the 10th European Conference on Infections in Leukaemia (ECIL), the guidelines for antifungal prophylaxis in pediatric and adult patients with hematological malignancies (HM) were updated and some changes introduced. Regarding acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients undergoing remission induction chemotherapy, a B-II grading has been assigned to isavuconazole, micafungin, and caspofungin, based on non-randomized studies that have shown efficacy in preventing invasive fungal diseases (IFD). Regarding high-risk MDS patients treated with azacytidine, prophylaxis with posaconazole during the first four cycles of treatment is supported in the literature. Prophylaxis is not indicated in patients treated for myeloproliferative neoplasms (NPM), acute lymphoid leukemia (ALL), and Hodgkin lymphoma (HL). For patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), prophylaxis is not generally indicated. For patients with multiple myeloma (MM), prophylaxis is not indicated and the limited epidemiological data available do not support the use of prophylaxis in subjects treated with bispecific antibodies. For patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), no substantial changes were made, apart from the addition of isavuconazole with grading B-II in the post-engraftment period. In patients undergoing auto-HSCT, antifungal prophylaxis is not indicated. Previous ECIL guidelines did not include CAR-T cells. The expert panel proposes to endorse the use of anti-mold prophylaxis in high-risk patients during pre-infusion and post-infusion, while in low-risk patients, anti-yeast prophylaxis can be recommended (B-II). For pediatric hematology patients, based on newly published data, caspofungin received a B-I grading as mold-active prophylaxis. Moreover, patients with ALL with insufficient treatment response during induction therapy, and children older than 12 y.o are now considered at high risk for IFD and are recommended to receive antifungal prophylaxis.
Human Cytomegalovirus Virion-Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients
Federica Giardina, Stefania Paolucci, Dalila Mele, Omar Mura, Marina Ramus, José Camilla Sammartino, Piera d'Angelo, Antonino Maria Guglielmo Pitrolo, Giulia Campanini, Eleonora Francesca Pattonieri, Teresa Rampino, Marilena Gregorini, Francesca Compagno, Domenica Federica Briganti, Elena Seminari, Nicola Polverelli, Irene Cassaniti, Daniele Lilleri, Fausto Baldanti
Journal of Medical Virology, 2025
Human Cytomegalovirus (HCMV) transcripts (including UL21.5 mRNA) have been found to be packaged in virions, and their detection in plasma may indicate the presence of infectious viral particles. The objective of this study was to verify whether UL21.5 mRNA detected in the plasma was indeed encapsulated in viral particles, representing an indirect marker of active replication. To distinguish between virion‐packaged and free‐floating RNA, plasma samples from 22 immunocompromised patients were tested before and after ribonuclease (RNAse) digestion. UL21.5 mRNA was detected 1–2 weeks before preemptive therapy administration in 20 episodes (from 18 patients) of clinically significant DNAemia, while it was undetectable in three of the four patients with transient, self‐resolving DNAemia. After RNAse digestion, UL21.5 mRNA was still detectable, with a median reduction of 0.1 (IQR: 0–0.3) Log10. Concentrations of UL21.5 mRNA in plasma correlated significantly with HCMV DNA in whole blood or plasma (R = 0.67), and 75% of samples positive for UL21.5 mRNA had HCMV DNA concentrations above 104 copies/mL blood or 103 copies/mL plasma. Moreover, UL21.5 mRNA was positive in patients who developed HCMV infection resistant to letermovir or maribavir, whereas it was undetectable in the plasma of patients with transient self‐resolving DNAemia blips during letermovir prophylaxis (not associated with drug‐resistance). HCMV UL21.5 mRNA in plasma is virion‐associated and represents a marker for productive HCMV infection. The determination of UL21.5 mRNA could improve current strategies for the management of HCMV infection in immunocompromised patients.
Port-a-Cath Infection of Mycobacterium senegalense: First Italian Case Report
Giulia Grassia, Francesco Amisano, Stefano Gaiarsa, Jessica Bagnarino, Francesca Compagno, Arianna Panigari, Fausto Baldanti, Vincenzina Monzillo, Daniela Barbarini
Microorganisms, 2024
Mycobacterium senegalense is a Non-Tuberculous Mycobacterium (NTM) belonging to the M. fortuitum group, often associated with veterinary diseases, such as bovine farcy. However, it can also cause human infections and appears to be involved in Catheter-Associated Infections in immunocompromised patients. Here, we report the first Italian isolation of a strain of M. senegalense from a 16-year-old oncological female patient being treated at Fondazione IRCCS Policlinico San Matteo Pavia (Italy). Following pain at the Port-a-Cath site, a pus culture was collected and the positivity for the M. fortuitum group revealed the NTM infection. Antimicrobial susceptibility tests were performed and interpreted according to the available CLSI breakpoints. This information allowed us to implement the correct antibiotic therapy that, together with the device removal, led to the patient’s recovery. Finally, due to the increasing number of isolations, the possible presence of NTM infections in prosthetic devices should be among the primary diagnostic questions in a clinical setting.
An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP)
Gianluca Dell’Orso, Marcello Carlucci, Simone Cesaro, Evelina Olcese, Adriana Balduzzi, Francesca Vendemini, Massimo Catti, Francesco Saglio, Francesca Compagno, Natalia Maximova, Marco Rabusin, Maria Cristina Menconi, Katia Perruccio, Elena Soncini, Francesco Paolo Tambaro, Veronica Tintori, Daria Pagliara, Maura Faraci
Bone Marrow Transplantation, 2024
Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation
Matteo Tanzi, Enrica Montini, Agnese Rumolo, Antonia Moretta, Patrizia Comoli, Gloria Acquafredda, Jessica Rotella, Gloria Taurino, Francesca Compagno, Francesco Delle Cave, Cesare Perotti, Gian Luigi Marseglia, Marco Zecca, Daniela Montagna
Cytotherapy, 2024
SARS-CoV-2 Infection in the Pediatric Oncology Population: The Definitive Comprehensive Report of the Infectious Diseases Working Group of AIEOP
Daniele Zama, Andrea Zanaroli, Agnese Corbelli, Andrea Lo Vecchio, Margherita Del Bene, Antonella Colombini, Francesca Compagno, Angelica Barone, Ilaria Fontanili, Maria Rosaria D’Amico, Maria Rosaria Papa, Maria Grazia Petris, Elisabetta Calore, Shana Montalto, Linda Meneghello, Letizia Brescia, Rosamaria Mura, Milena La Spina, Paola Muggeo, Simona Rinieri, Cristina Meazza, Katia Perruccio, Monica Cellini, Manuela Spadea, Federico Mercolini, Valeria Petroni, Raffaella De Santis, Elena Soncini, Massimo Provenzi, Nagua Giurici, Ottavio Ziino, Gloria Tridello, Simone Cesaro
Journal of Infectious Diseases, 2024
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia
Anne Bergeron, Malgorzata Mikulska, Julien De Greef, Louise Bondeelle, Tomas Franquet, Jean-Louis Herrmann, Christoph Lange, Isabel Spriet, Murat Akova, J Peter Donnelly, Johan Maertens, Georg Maschmeyer, Montserrat Rovira, Delia Goletti, Rafael de la Camara, Hildegard Greinix, Johan Maertens, Julien De Greef, Monica Slavin, Isabel Spriet, Petr Hubacek, Anne Bergeron, Catherine Cordonnier, Jukka Kanerva, Raoul Herbrecht, Jean-Louis Herrmann, Fanny Lanternier, Louise Bondeelle, Christine Robin, Hermann Einsele, Thomas Lehrnbecher, Andreas Groll, Georg Maschmeyer, Christoph Lange, Marie von Lilienfeld-Toal, Dorothea Pana, Emmanuel Roilides, Csaba Kassa, Diana Averbuch, Dan Engelhard, Simone Cesaro, Malgorzata Mikulska, Livio Pagano, Elio Castagnola, Francesca Compagno, Delia Goletti, Alessio Mesini, Peter J Donnelly, Jan Styczynski, Aida Botelho de Sousa, Mahmoud Aljurf, Rafael de la Camara, David Navarro, Montserrat Rovira, Tomas Franquet, Carol Garcia-Vidal, Per Ljungman, Karlis Paukssen, Roland Ammann, Frédéric Lamoth, Hans Hirsch, Nicole Ritz, Murat Akova, Mansour Ceesay, Adilia Warris, Roy Chemaly
Lancet Infectious Diseases, 2022
Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
Daniele Zama, Francesco Baccelli, Antonella Colombini, Amalia Contino, Elisabetta Calore, Maria Grazia Petris, Linda Meneghello, Federico Mercolini, Andrea Lo Vecchio, Shana Montalto, Cristina Meazza, Angelica Barone, Francesca Compagno, Paola Muggeo, Elena Soncini, Letizia Brescia, Eugenia Giraldi, Nagua Giurici, Rosa Maria Mura, Monica Cellini, Katia Perruccio, Valeria Petroni, Milena La Spina, Ottavio Ziino, Roberta Burnelli, Raffaella De Santis, Maurizio Mascarin, Valentina Barretta, Gloria Tridello, Simone Cesaro
Annals of Hematology, 2022
Consensus on COVID‐19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology
Simone Cesaro, Paola Muggeo, Daniele Zama, Monica Cellini, Katia Perruccio, Antonella Colombini, Francesca Carraro, Maria Grazia Petris, Valeria Petroni, Maurizio Mascarin, Francesco Baccelli, Elena Soncini, Rosamaria Mura, Milena La Spina, Nunzia Decembrino, Roberta Burnelli, Stefano Frenos, Elio Castagnola, Maura Faraci, Cristina Meazza, Federica Barzaghi, Maria Rosaria D’Amico, Maria Capasso, Elisabetta Calore, Ottavio Ziino, Angelica Barone, Francesca Compagno, Laura Luti, Federica Galaverna, Raffaella De Santis, Letizia Brescia, Linda Meneghello, Angelamaria Petrone, Nagua Giurici, Daniela Onofrillo, Fabian Schumacher, Federico Mercolini
Journal of Clinical Medicine, 2022
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
Sheena Mukkada, Nickhill Bhakta, Guillermo L Chantada, Yichen Chen, Yuvanesh Vedaraju, Lane Faughnan, Maysam R Homsi, Hilmarie Muniz-Talavera, Radhikesh Ranadive, Monika Metzger, Paola Friedrich, Asya Agulnik, Sima Jeha, Catherine Lam, Rashmi Dalvi, Laila Hessissen, Daniel C Moreira, Victor M Santana, Michael Sullivan, Eric Bouffet, Miguela A Caniza, Meenakshi Devidas, Kathy Pritchard-Jones, Carlos Rodriguez-Galindo, A Juan Ribelles, Adriana Balduzzi, Alaa Elhaddad, Alejandra Casanovas, Alejandra Garcia Velazquez, Aliaksandra Laptsevich, Alicia Chang, Alessandra Lamenha F. Sampaio, Almudena González Prieto, Alvaro Lassaletta, Amaranto Suarez M, Ana Patricia Alcasabas, Anca Colita, Andres Morales La Madrid, Angélica Samudio, Annalisa Tondo, Antonella Colombini, Antonis Kattamis, N Araceli Lopez Facundo, Arpita Bhattacharyya, Aurélia Alimi, Aurélie Phulpin, Barbora Vakrmanova, Basak A Aksoy, Benoit Brethon, Jator Brian Kobuin, Carla Nolasco Monteiro, Catherine Paillard, Catherine Vezina, Bozkurt Ceyhun, Cristiana Hentea, Cristina Meazza, Daniel Ortiz-Morales, Roque Daniel Solorzano, Daniela Arce Cabrera, Daniele Zama, Debjani Ghosh, Diana Ramírez-Rivera, Doris A Calle Jara, Dragana Janic, Elianneth Rey Helo, Elodie Gouache, Enmanuel Guerrero Quiroz, Enrique Lopez, Eric Thebault, Essy Maradiegue, Eva de Berranger, Fatma S E Ebeid, Federica Galaverna, Federico Antillon-Klussmann, Felipe Espinoza Chacur, Fernando Daniel Negro, Francesca Carraro, Francesca Compagno, Francisco Barriga, Gabriela Tamayo Pedraza, Gissela Sanchez Fernandez, Gita Naidu, Gülnur Tokuc, Hamidah Alias, Hannah Grace B Segocio, Houda Boudiaf, Imelda Asetre Luna, Iris Maia, Itziar Astigarraga, Ivan Maza, Jacqueline E Montoya Vásquez, Janez Jazbec, Jelena Lazic, Jeniffer Beck Dean, Jeremie Rouger-Gaudichon, Johanny Carolina Contreras González, Jorge Huerta Aragonés, José L Fuster, Juan Quintana, Julia Palma, Karel Svojgr, Karina Quintero, Karolina Malic Tudor, Kleopatra Georgantzi, Kris Ann P Schultz, Laura Ureña Horno, Lidia Fraquelli, Linda Meneghello, Lobna Shalaby, Lola L Macias Mora, Lorna A Renner, Luciana Nunes Silva, Luisa Sisinni, Mahmoud Hammad, M Fernández Sanmartín, C Marcela Zubieta A, María Constanza Drozdowski, Maria Kourti, Marcela María Palladino, Maria R Miranda Madrazo, Marilyne Poiree, Marina Popova, Mario Melgar, Marta Baragaño, Martha J Avilés-Robles, Massimo Provenzi, Mecneide Mendes Lins, Mehmet Fatih Orhan, Milena Villarroel, Mónica Jerónimo, Mónica Varas Palma, Muhammad Rafie Raza, Mulindwa M Justin, Najma Shaheen, Nerea Domínguez-Pinilla, Nicholas S Whipple, Nicolas André, Ondrej Hrusak, Pablo Velasco Puyó, Pamela Zacasa Vargas, Paola Olate Mellado, Pascale Yola Gassant, Paulina Diaz Romero, Raffaella De Santis, Rejin Kebudi, Riza Boranbayeva, Roberto Vasquez, Romel A. Segura, Roy Enrique Rosado, Sandra Gómez, Sandra Raimbault, Sanjeeva Gunasekera, Sara M Makkeyah, Sema Buyukkapu Bay, Sergio M Gómez, Séverine Bouttefroy, Shahnoor Islam, Sherif Abouelnaga, Silvio Fabio Torres, Simone Cesaro, Sofia Nunes, Soraia Rouxinol, Sucharita Bhaumik, Symbat Saliyeva, Tamara Inostroza, Thelma Velasquez, Tint Myo Hnin, Ulrika Norén-Nyström, Valentina Baretta, Yajaira Valentine Jimenez-Antolinez, Vanesa Pérez Alonso, Vanessa Ayer Miller, Virginie Gandemer, Viviana Lotero, Volha Mishkova, Wendy Gómez-García, Yeva Margaryan, Yumna Syed
Lancet Oncology, 2021
Human Herpesvirus 6 Encephalitis in Immunocompetent and Immunocompromised Hosts
Giulia Berzero, Giulia Campanini, Elisa Vegezzi, Matteo Paoletti, Anna Pichiecchio, Anna Maria Simoncelli, Anna Amelia Colombo, Paolo Bernasconi, Oscar Borsani, Angela Di Matteo, Virginia Rossi, Thomas Foiadelli, Salvatore Savasta, Francesca Compagno, Marco Zecca, Fausto Baldanti, Enrico Marchioni
Neurology Neuroimmunology and Neuroinflammation, 2021
Association of immune thrombocytopenia and celiac disease in children: A retrospective case control study
Angela Guarina, Maddalena Marinoni, Giuseppe Lassandro, Paola Saracco, Silverio Perrotta, Elena Facchini, Lucia Dora Notarangelo, Giovanna Russo, Paola Giordano, Francesca Romano, Elisa Bertoni, Chiara Gorio, Gianluca Boscarol, Milena Motta, Marco Spinelli, Angelica Barone, Marco Zecca, Francesca Compagno, Saverio Ladogana, Angela Maggio, Maurizio Miano, Gianluca Dell’orso, Elena Chiocca, Ilaria Fotzi, Angela Petrone, Assunta Tornesello, Irene D’alba, Silvia Salvatore, Maddalena Casale, Giuseppe Puccio, Ugo Ramenghi, Piero Farruggia
Turkish Journal of Hematology, 2021
Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation
Sabrina Basso, Francesca Compagno, Paola Zelini, Giovanna Giorgiani, Stella Boghen, Elena Bergami, Jessica Bagnarino, Mariangela Siciliano, Claudia Del Fante, Mario Luppi, Marco Zecca, Patrizia Comoli
Frontiers in Immunology, 2020
Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
Francesca Compagno, Sabrina Basso, Arianna Panigari, Jessica Bagnarino, Luca Stoppini, Alessandra Maiello, Tommaso Mina, Paola Zelini, Cesare Perotti, Fausto Baldanti, Marco Zecca, Patrizia Comoli
Frontiers in Immunology, 2020
Screening for SARS-CoV-2 infection in pediatric oncology patients during the epidemic peak in Italy
Simone Cesaro, Francesca Compagno, Daniele Zama, Linda Meneghello, Nagua Giurici, Elena Soncini, Daniela Onofrillo, Federico Mercolini, Rossella Mura, Katia Perruccio, Raffaella De Santis, Antonella Colombini, Angelica Barone, Laura Sainati, Valentina Baretta, Maria Grazia Petris
Pediatric Blood and Cancer, 2020
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy
Andrea Ferrari, Marco Zecca, Carmelo Rizzari, Fulvio Porta, Massimo Provenzi, Maddalena Marinoni, Richard Fabian Schumacher, Roberto Luksch, Monica Terenziani, Michela Casanova, Filippo Spreafico, Stefano Chiaravalli, Francesca Compagno, Federica Bruni, Chiara Piccolo, Laura Bettini, Mariella D'Angiò, Giulia Maria Ferrari, Andrea Biondi, Maura Massimino, Adriana Balduzzi
Pediatric Blood and Cancer, 2020
Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases
Marie von Lilienfeld-Toal, , Jörg Janne Vehreschild, Oliver Cornely, Livio Pagano, Francesca Compagno, Hans H. Hirsch
Leukemia, 2020
Diagnosing acute encephalitis in patients with hematological disorders: caveats and pitfalls
Elisa Vegezzi, Giulia Berzero, Desiree Barbetta, Anna Amelia Colombo, Oscar Borsani, Paolo Bernasconi, Francesca Compagno, Marco Zecca, Giulia Campanini, Anna Simoncelli, Matteo Paoletti, Anna Pichiecchio, Fausto Baldanti, Enrico Brunetti, Enrico Marchioni
Journal of Neurovirology, 2020
Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in italian pediatric oncology patients: A study from the infectious diseases working group of the associazione italiana di oncologia e ematologia pediatrica
Gianni Bisogno, Massimo Provenzi, Daniele Zama, Annalisa Tondo, Cristina Meazza, Antonella Colombini, Federica Galaverna, Francesca Compagno, Francesca Carraro, Raffaela De Santis, Linda Meneghello, Valentina Baretta, Simone Cesaro
Journal of the Pediatric Infectious Diseases Society, 2020
Generation of donor-derived Wilms tumor antigen 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study
Federica Ferulli, Matteo Tanzi, Ilaria Turin, Enrica Montini, Vittorio Rosti, Gloria Acquafredda, Daniela Lisini, Francesca Compagno, Stella Boghen, Amelia Licari, Gianluigi Marseglia, Marco Zecca, Daniela Montagna
Cytotherapy, 2019
The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study
Francesca Compagno, Klaudia Naegele, Christian R. Kahlert, Irene Hsli, Karoline Aebi-Popp, Begona Martinez de Tejada, Paolo Paioni, Sabine Yerly, Jrg Bni, Manuel Battegay, Christoph Rudin, Hans H. Hirsch, Swiss HIV Cohort Study
Swiss Medical Weekly, 2019
Community-acquired respiratory paramyxovirus infection after allogeneic hematopoietic cell transplantation: A single-center experience
Yasmin Spahr, Sarah Tschudin-Sutter, Veronika Baettig, Francesca Compagno, Michael Tamm, Jörg Halter, Sabine Gerull, Jakob Passweg, Hans H Hirsch, Nina Khanna
Open Forum Infectious Diseases, 2018
De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
Michela Cioni, Arcangelo Nocera, Annalisa Innocente, Augusto Tagliamacco, Antonella Trivelli, Sabrina Basso, Giuseppe Quartuccio, Iris Fontana, Alberto Magnasco, Francesca Drago, Antonella Gurrado, Ilaria Guido, Francesca Compagno, Giacomo Garibotto, Catherine Klersy, Enrico Verrina, Gian Marco Ghiggeri, Massimo Cardillo, Patrizia Comoli, Fabrizio Ginevri
Journal of Immunology Research, 2017
Long-term prognosis of patients with Ehlers-Danlos syndrome and epilepsy
Alberto Verrotti, Maria Valentina Spartà, Debora Monacelli, Rossella Porto, Miriam Castagnino, Annalisa Russo Raucci, Francesca Compagno, Simona Viglio, Thomas Foiadelli, Francesco Nicita, Salvatore Grosso, Alberto Spalice, Francesco Chiarelli, Gianluigi Marseglia, Salvatore Savasta
Epilepsia, 2014